CPI-1612 is an orally bioavailable EP300/CBP histone acetyltransferase inhibitor. CREBBP/EP300 acetyltransferase inhibition by CPI-1612 potently suppresses in vitro and in vivo growth of breast cancer cell line models and acts in a manner orthogonal to directly targeting ER. CREBBP/EP300 acetyltransferase inhibition suppresses ER-dependent transcription by targeting lineage-specific enhancers defined by the pioneer transcription factor FOXA1.
MedKoo Cat#: 593206
Name: CPI-1612
CAS#: 2374971-81-8
Chemical Formula: C27H26N6O
Exact Mass: 450.2168
Molecular Weight: 450.55
Elemental Analysis: C, 71.98; H, 5.82; N, 18.65; O, 3.55
The following data is based on the product molecular weight 450.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
